## APPENDIX TABLE. AVERAGE MONTHLY USE AND ANNUALIZED MONTHLY GROWTH RATES OF GLITAZONES.

|                          | Glitazones          | Rosiglitazone        | Pioglitazone         |
|--------------------------|---------------------|----------------------|----------------------|
|                          | Level† (95% CI)     | Annualized Growth Rate‡ (95% CI) | Level† (95% CI)     | Annualized Growth Rate‡ (95% CI) | Level† (95% CI)     | Annualized Growth Rate‡ (95% CI) |
| **Jan, 2003 – Jan, 2005** | 779 (740 - 818)     | 22.0 (19.2 - 24.9)** | 432 (400 - 465)     | 31.5 (23.9 - 39.1)**              | 347 (338 - 356)     | 13.8 (8.0 - 19.6)**              |
| **Feb, 2005 – Jan, 2007** | 929 (919 – 940)     | -2.2 (-4.1 - -0.3)*  | 461 (445 - 478)     | -15.5 (-20.2 - -10.7)**            | 468                  | 13.7 (9.2 - 18.3)**              |
| **Feb, 2007 – May, 2008** | 721 (668 – 774)     | -28.7 (-30.9 - -26.5)** | 226 (175 - 277)     | -60.2 (-63.9 - -56.4)**            | 495                  | -8.6 (-16.9 - -0.3)*             |
| **June, 2008 – June, 2009** | 577 (570 – 583)     | -1.8 (-8.8 - 5.2)    | 135 (129 - 142)     | 10.7 (-1.7 - 23.1)                | 441                  | -7.1 (-22.6 - 8.5)               |

†Treatment Visits Levels are in thousands. ‡Figures are annualized monthly growth rates over pre-defined segments. ** significant at 1% and * significant at 5%.

Source: IMS Health, National Disease and Therapeutic Index™, 2003-2009